New stroke drug shows promise in recovery trial

NCT ID NCT05289947

Completed Disease control Sponsor: Moleac Pte Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called MLC1501 to help people recover after a stroke. 303 adults who had a stroke within the past 2 to 10 days took either a high dose, low dose, or a placebo pill twice a day for 24 weeks. The main goal was to see if MLC1501 improves motor function and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Embolic Stroke intracranial embolism ischemic stroke myocardial infarction stroke disorder Thrombotic Stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE STROKE SEQUELAE STROKE, CARDIOVASCULAR STROKE, CRYPTOGENIC STROKE, EMBOLIC STROKE, ISCHEMIC STROKES THROMBOTIC

Contacts and locations

Locations

Baguio General Hospital and Medical Center

Baguio City, Philippines
Changi General Hospital

Singapore, Singapore, Singapore
Jose R. Reyes Memorial Medical Center

Manila, Philippines
Manila Doctors Hospita

Manila, Philippines
Metro Davao Medical And Research Center

Davao City, Davao Region, Philippines
National Neuroscience Institute (NNI) @ Tan Tock Seng Hospital (TTSH)

Singapore, Singapore, Singapore
Quirino Memorial Medical Center

Manila, Manila, Philippines
Raffles Hospital

Singapore, Singapore
Singapore General Hospital

Singapore, Singapore
University of Santo Tomas Hospital

Manila, Manila, Philippines
West Visayas State University Medical Center

Iloilo City, Philippines

More trials for these conditions

Other studies related to the condition(s) this trial covers.